First DR3 blocker in the clinic posts best-in-class immunogenicity; Phase 2b in Crohn's disease will confirm or disprove whether that translates to efficacy

Shattuck Labs is a clinical-stage company developing a targeted immunology drug to treat Crohn's disease, which is not yet approved.

SL-325, the first DR3-blocking antibody in human testing, posted a 3.7% ADA rate and complete receptor occupancy supporting quarterly dosing, differentiated early benchmarks in a crowded TL1A/DR3 field. The thesis resolves on whether the 232-patient RECEPTIVE-CD1 trial hits endoscopic response at Week 12, establishing that DR3 blockade drives clinical benefit in Crohn's disease. With $208M cash and a 2029 runway, survival is not the risk; the risk is that a single-mechanism Phase 2b without prior efficacy data fails to prove the concept.